Clinical value of whole-body PET/CT in patients with active rheumatic diseases.
about
Fludeoxyglucose positron emission tomography-computed tomography scan showing polyarthritis in a patient with an atypical presentation of Henoch-Schönlein vasculitis without clinical signs of arthritis: a case report.18F-FDG PET/CT for identifying the potential causes and extent of secondary hemophagocytic lymphohistiocytosisAssociation of Remitting Seronegative Symmetrical Synovitis with Pitting Edema, Polymyalgia Rheumatica, and Adenocarcinoma of the ProstateMultiple values of (18)F-FDG PET/CT in idiopathic inflammatory myopathy.Treatment of adult-onset still's disease: up to date.18F-FDG PET/CT in polymyalgia rheumatica-a pictorial review.The clinical utility of splenic fluorodeoxyglucose uptake for diagnosis and prognosis in patients with macrophage activation syndrome."To be or not to be" for PET in rheumatology. A marriage of love or of convenience?Quantitative Metabolic Volumetric Product on 18Fluorine-2fluoro-2-deoxy-D-glucose-positron Emission Tomography/Computed Tomography in Assessing Treatment Response to Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Multiparametric AnalUtility and drawbacks of [18]F-fluorodeoxyglucose positron emission tomography in the evaluation of adult-onset Still's disease.Positron Emission Tomography as an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients with Large Vessel Vasculitis.Utility of 18F-fluoro-dexoxyglucose positron emission tomography for the diagnosis of polymyalgia rheumatica: a controlled study.Value of (18)F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment.
P2860
Q36960661-D21166C2-1BCF-47DD-A72D-A41FED4275CDQ37249815-13BC0669-9957-4F62-B1EC-A9A8048326AEQ38285371-24D660D1-2E41-4BA2-987C-2CAD19B30747Q38613068-BF899FD6-7EC1-4009-BB12-9E6FBB06EA2FQ38679486-AC509A72-5215-4B9F-91B6-BB74F2042255Q39309315-C9D063D1-E93D-49FB-8068-7B7D69AB8DA8Q40082328-7B1EC9B2-E07A-4952-BDE9-A53CB3423018Q42367054-CDBFAD4A-DB86-4369-A6CF-83C4824545BFQ42376463-B2C2ED94-A0FB-4E46-BE6B-561D588E6635Q45407846-B11BDBCC-9A31-46CA-8008-2290C32F1152Q47836073-273A2E67-19E1-49BA-B8B0-E0E83294EC6EQ52983436-EEFE0498-C35F-48A5-8C47-6EAF0916E033Q52985774-C92A2DB5-D2CB-4DEF-8725-6B5A008B0BC4
P2860
Clinical value of whole-body PET/CT in patients with active rheumatic diseases.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Clinical value of whole-body PET/CT in patients with active rheumatic diseases.
@ast
Clinical value of whole-body PET/CT in patients with active rheumatic diseases.
@en
Clinical value of whole-body PET/CT in patients with active rheumatic diseases.
@nl
type
label
Clinical value of whole-body PET/CT in patients with active rheumatic diseases.
@ast
Clinical value of whole-body PET/CT in patients with active rheumatic diseases.
@en
Clinical value of whole-body PET/CT in patients with active rheumatic diseases.
@nl
prefLabel
Clinical value of whole-body PET/CT in patients with active rheumatic diseases.
@ast
Clinical value of whole-body PET/CT in patients with active rheumatic diseases.
@en
Clinical value of whole-body PET/CT in patients with active rheumatic diseases.
@nl
P2093
P2860
P1476
Clinical value of whole-body PET/CT in patients with active rheumatic diseases.
@en
P2093
Akio Mimori
Hiroyuki Yamashita
Kazuo Kubota
P2860
P2888
P356
10.1186/S13075-014-0423-2
P577
2014-01-01T00:00:00Z
P5875
P6179
1049058267